Expression of LMO4 and outcome in pancreatic ductal adenocarcinoma
Identification of a biomarker of prognosis and response to therapy that can be assessed preoperatively would significantly improve overall outcomes for patients with pancreatic cancer. In this study, patients whose tumours exhibited high LMO4 expression had a significant survival advantage following operative resection, whereas the survival of those patients whose tumours had low or no LMO4 expression was not significantly different when resection was compared with operative biopsy alone.British Journal of Cancer (2008) 98, 537-541. doi:10.1038/sj.bjc.6604177 www.bjcancer.com Published online 29 January 2008.
|Authors||Murphy, N. C.;Scarlett, C. J.;Kench, J. G.;Sum, E. Y.;Segara, D.;Colvin, E. K.;Susanto, J.;Cosman, P. H.;Lee, C. S.;Musgrove, E. A.;Sutherland, R. L.;Lindeman, G. J.;Henshall, S. M.;Visvader, J. E.;Biankin, A. V. :|
|Publisher Name||BRITISH JOURNAL OF CANCER|
|URL link to publisher's version||http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18231110|
|OpenAccess link to author's accepted manuscript version||https://publications.gimr.garvan.org.au/open-access/2366|